Pieris Pharmaceuticals Management
Management Kriterienprüfungen 3/4
Pieris Pharmaceuticals' CEO ist Steve Yoder , ernannt in Dec 2014, hat eine Amtszeit von 9.5 Jahren. Die jährliche Gesamtvergütung beträgt $1.36M , bestehend aus 43% Gehalt und 57% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.006% der Aktien des Unternehmens, im Wert von $727.41 . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 4.7 Jahre bzw. 6.6 Jahre.
Wichtige Informationen
Steve Yoder
Geschäftsführender
US$1.4m
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | 43.0% |
| Amtszeit als Geschäftsführer | 9.5yrs |
| Eigentum des Geschäftsführers | 0.006% |
| Durchschnittliche Amtszeit des Managements | 4.7yrs |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 6.6yrs |
Jüngste Management Updates
Recent updates
Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 27% Share Price Plunge
Apr 21
We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully
Mar 19Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Not Doing Enough For Some Investors As Its Shares Slump 27%
Dec 18We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully
Aug 18Analysts Just Shaved Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts Dramatically
May 15Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 41% Share Price Plunge
Apr 17Can Pieris Pharmaceuticals (NASDAQ:PIRS) Afford To Invest In Growth?
Dec 31Bearish: This Analyst Is Revising Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Revenue and EPS Prognostications
Aug 10Pieris Pharmaceuticals GAAP EPS of -$0.14 misses by $0.03, revenue of $3.7M misses by $6.77M
Aug 04Pieris: Early Stage Developer Of Novel Asset Class
Jan 09We're Not Very Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate
Dec 15Progress At Pieris Pharmaceuticals
Oct 27Analysts Just Made A Noticeable Upgrade To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts
Aug 05We Think Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) CEO Compensation Package Needs To Be Put Under A Microscope
Jun 19Need To Know: Analysts Just Made A Substantial Cut To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Estimates
May 22Will Pieris Pharmaceuticals (NASDAQ:PIRS) Spend Its Cash Wisely?
May 19Analysts Are Betting On Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) With A Big Upgrade This Week
Apr 01Here's What Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Shareholder Ownership Structure Looks Like
Mar 08We're Keeping An Eye On Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate
Feb 01How Much Did Pieris Pharmaceuticals'(NASDAQ:PIRS) Shareholders Earn From Share Price Movements Over The Last Three Years?
Dec 28
How Does Pieris Pharmaceuticals' (NASDAQ:PIRS) CEO Salary Compare to Peers?
Dec 02Analyse der Geschäftsführervergütung
| Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$16m |
| Dec 31 2023 | US$1m | US$585k | -US$25m |
| Sep 30 2023 | n/a | n/a | -US$28m |
| Jun 30 2023 | n/a | n/a | -US$27m |
| Mar 31 2023 | n/a | n/a | -US$41m |
| Dec 31 2022 | US$2m | US$565k | -US$33m |
| Sep 30 2022 | n/a | n/a | -US$35m |
| Jun 30 2022 | n/a | n/a | -US$42m |
| Mar 31 2022 | n/a | n/a | -US$47m |
| Dec 31 2021 | US$2m | US$548k | -US$46m |
| Sep 30 2021 | n/a | n/a | -US$51m |
| Jun 30 2021 | n/a | n/a | -US$48m |
| Mar 31 2021 | n/a | n/a | -US$38m |
| Dec 31 2020 | US$2m | US$535k | -US$37m |
| Sep 30 2020 | n/a | n/a | -US$26m |
| Jun 30 2020 | n/a | n/a | -US$15m |
| Mar 31 2020 | n/a | n/a | -US$22m |
| Dec 31 2019 | US$2m | US$515k | -US$28m |
| Sep 30 2019 | n/a | n/a | -US$36m |
| Jun 30 2019 | n/a | n/a | -US$40m |
| Mar 31 2019 | n/a | n/a | -US$28m |
| Dec 31 2018 | US$3m | US$500k | -US$27m |
| Sep 30 2018 | n/a | n/a | -US$8m |
| Jun 30 2018 | n/a | n/a | -US$8m |
| Mar 31 2018 | n/a | n/a | -US$18m |
| Dec 31 2017 | US$1m | US$450k | -US$18m |
Vergütung im Vergleich zum Markt: SteveDie Gesamtvergütung ($USD1.36M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD673.68K).
Entschädigung vs. Einkommen: SteveDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.
Geschäftsführer
Steve Yoder (48 yo)
9.5yrs
Amtszeit
US$1,358,952
Vergütung
Mr. Stephen S. Yoder, also known as Steve, J.D., has been the Chief Executive Officer and President at Pieris Pharmaceuticals, Inc. since December 17, 2014. Mr. Yoder joined Pieris Pharmaceuticals GmbH as...
Führungsteam
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| CEO, President & Director | 9.5yrs | US$1.36m | 0.0057% $ 692.5 | |
| Senior VP | 4.8yrs | US$729.04k | 0.018% $ 2.2k | |
| Senior VP & Chief Development Officer | no data | US$705.45k | 0.0044% $ 535.2 | |
| Executive Director of Investor Relations | no data | keine Daten | keine Daten | |
| Chief Supply Chain Officer | 4.7yrs | keine Daten | keine Daten | |
| VP and Head of Alliance Management & Early Project Leadership | 1.4yrs | keine Daten | keine Daten |
4.7yrs
Durchschnittliche Betriebszugehörigkeit
48yo
Durchschnittliches Alter
Erfahrenes Management: PIRSDas Führungsteam des Unternehmens gilt als erfahren (4.7 Jahre durchschnittliche Betriebszugehörigkeit).
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| CEO, President & Director | 9.5yrs | US$1.36m | 0.0057% $ 692.5 | |
| Independent Chairman | 7.1yrs | US$94.09k | 0.019% $ 2.3k | |
| Independent Director | 9.5yrs | US$52.09k | 0% $ 0 | |
| Independent Director | 7.8yrs | US$72.58k | 0.019% $ 2.3k | |
| Independent Director | 5.8yrs | US$65.08k | 0% $ 0 | |
| Independent Director | 5.7yrs | US$53.09k | 0% $ 0 | |
| Independent Director | 6.2yrs | US$52.09k | 0% $ 0 | |
| Independent Director | 4.9yrs | US$52.09k | 0% $ 0 | |
| Member of Clinical & Scientific Advisory Board | no data | keine Daten | keine Daten | |
| Member of Clinical & Scientific Advisory Board | no data | keine Daten | keine Daten | |
| Member of Clinical & Scientific Advisory Board | no data | keine Daten | keine Daten | |
| Member of Clinical & Scientific Advisory Board | no data | keine Daten | keine Daten |
6.6yrs
Durchschnittliche Betriebszugehörigkeit
61.5yo
Durchschnittliches Alter
Erfahrener Vorstand: PIRSDie Vorstandsmitglieder gelten als erfahren (6.6 Jahre durchschnittliche Amtszeit).